JB/CALL/MODERNA/110/0.0166/20.12.24 | Real-time Bid/Ask 03:54:28 2024-05-29 EDT | ||
| 0.8 CHF / 0.81 CHF | -0.62% |
|
| Current month | +131.43% | ||
| 1 month | +179.31% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 24-05-28 | 0.81 | -19.00% |
| 24-05-27 | 1 | +1.01% |
| 24-05-24 | 0.99 | +5.32% |
| 24-05-23 | 0.94 | +6.82% |
| 24-05-22 | 0.88 | +41.94% |
Delayed Quote Swiss Exchange
Last update May 28, 2024 at 11:20 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | Bank Julius Bär |
| MRNZJB | |
| ISIN | CH1298672796 |
| Date issued | 2023-10-19 |
| Strike | 110 $ |
| Maturity | 2024-12-20 (206 Days) |
| Parity | 60 : 1 |
| Emission price | 0.22 CHF |
| Emission volume | N/A |
| Settlement | cash |
| Currency | CHF |
Technical Indicators
| Highest since issue | 1 CHF |
|---|---|
| Lowest since issue | 0.12 CHF |
| Spread | 0.01 CHF |
| Spread % | 1.22% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
153.2
USD
Average target price
138.5
USD
Spread / Average Target
-9.59%
- Stock Market
- Warrants
- MRNZJB Warrant
